Aru Narendran
Overview
Explore the profile of Aru Narendran including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
91
Citations
3549
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Wang B, Li D, Cherkasova V, Gerasymchuk M, Narendran A, Kovalchuk I, et al.
Cancers (Basel)
. 2022 Apr;
14(8).
PMID: 35454815
High-risk neuroblastoma is an aggressive pediatric tumor. Despite great advances in neuroblastoma therapy and supportive care protocols, no curative treatment is available for most patients with this disease. Here, we...
12.
Reynolds C, Tran S, Jain M, Narendran A
Vaccines (Basel)
. 2022 Feb;
10(2).
PMID: 35214655
Alternatives to conventional cancer treatments are highly sought after for high-risk malignancies that have a poor response to established treatment modalities. With research advancing rapidly in the past decade, neoantigen-based...
13.
Thakur S, Jain M, Zhang C, Major C, Bielamowicz K, Lacayo N, et al.
Hum Vaccin Immunother
. 2021 Nov;
17(12):5558-5562.
PMID: 34844524
There is experimental and clinical data to indicate the contribution of immune-escape mechanisms in relapsed/refractory pediatric leukemia. Studies have shown the accumulation of mutations that translate to peptides containing tumor-specific...
14.
Tran S, Truong T, Narendran A
Eur J Cancer
. 2021 Nov;
159:259-274.
PMID: 34798454
Background: Efficacy and safety data of COVID-19 vaccines among cancer populations have been limited; however, preliminary data from recent studies have emerged regarding their immunogenicity and safety in this population....
15.
Banderali U, Jain M, Thakur S, Jayanthan A, Belke D, Giles W, et al.
Curr Eye Res
. 2021 Oct;
47(3):426-435.
PMID: 34674590
Purpose: Retinoblastoma is the most frequent intraocular cancer in children. It is also one of the most common causes for enucleation and carries a significant morbidity rate in affected individuals....
16.
Al-Ghabkari A, Narendran A
Cancer Biol Ther
. 2021 May;
22(4):333-344.
PMID: 33978549
Enhancer of zeste homolog 2 (EZH2) is a histone methyltransferase and a catalytic subunit of the polycomb repressive complex 2 (PRC2) that catalyzes the mono-, di-, and tri-methylation of histone...
17.
Cytotoxicity and Target Modulation in Pediatric Solid Tumors by the Proteasome Inhibitor Carfilzomib
Thakur S, Ruan Y, Jayanthan A, Boklan J, Narendran A
Curr Cancer Drug Targets
. 2021 May;
21(9):804-811.
PMID: 33949932
Background: Most children with recurrent metastatic solid tumors have high mortality rates. Recent studies have shown that proteasome inhibition leads to effective tumor killing in cells that have acquired treatment...
18.
Jain M, Tran S, Thakur S, Nagashima Y, Anderson R, Narendran A
Neurooncol Adv
. 2021 Jan;
3(1):vdaa174.
PMID: 33506207
No abstract available.
19.
Perreault S, Chami R, Deyell R, El Demellawy D, Ellezam B, Jabado N, et al.
Curr Oncol
. 2021 Jan;
28(1):346-366.
PMID: 33435412
Neurotrophic tyrosine receptor kinase gene fusions () are oncogenic drivers present at a low frequency in most tumour types (<5%), and at a higher frequency (>80%) in a small number...
20.
Hecht A, Meyer J, Behnert A, Wong E, Chehab F, Olshen A, et al.
Haematologica
. 2020 Dec;
107(1):178-186.
PMID: 33375775
Mutations in the gene CBL were first identified in adults with various myeloid malignancies. Some patients with juvenile myelomonocytic leukemia (JMML) were also noted to harbor mutations in CBL, but...